Navigation Links
Genetic Immunity To Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/9/2008

MCLEAN, Va. and BUDAPEST, Hungary, May 9 /PRNewswire/ -- Genetic Immunity, a US/Hungarian clinical-stage Company focused on the development of its patented nanomedicines for targeted immune amplification, announced today that the Company will be presenting at the Rodman & Renshaw 5th Annual Global Healthcare Conference to be held May 19-20, 2008 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. The Company's President and Chief Executive Officer, Dr. Julianna Lisziewicz, is scheduled to present an overview of the Company's clinical programs on Monday, May 19 at 9:20 a.m. CEST in the Atlantique Salon, Eastern (2nd floor).

For more information on this event please visit:

http://www.rodmanandrenshaw.com/conferences.

About Genetic Immunity(R)

Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical company establishing leadership in Nanomedicines for targeted immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues, such as bone, muscle, or nerve. The Company aims to discover, develop and commercialize topically administered nanomedicines that can create new markets for treating infectious diseases, cancer and allergies. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. The DermaVir Patch, Genetic Immunity's lead nanomedicine candidate, is in Phase II clinical development and could be the first nanomedicine immune therapy approved for HIV-infected individuals. The DermaVir Patch has demonstrated excellent safety, immunogenicity and antiviral efficacy in preclinical studies. Phase I/II trials to date have confirmed safety and tolerability and indicate the induction of long-lasting HIV-specific T cells.

About the Nanomedicine Technology Platform

Genetic Immunity's nanomedicine immune amplification platform technology is comprised of two principal components: NanoComp and DermaPrep. NanoComp is a patented nanoformulation technology that includes disease-specific plasmid DNA encoded antigens. DermaPrep is the topical administration device that delivers NanoComp into a patient's lymph node dendritic cells to induce T cell mediated immune responses that can treat a broad spectrum of diseases. These two components together make up the DermaVir Patch. The plasmid DNA within DermaVir Patch's NanoComp nanoparticles is specific to HIV and topically delivered via DermaPrep to amplify the immune system to kill only HIV-infected cells.

http://www.geneticimmunity.com

Contacts:

The Ruth Group

Investors Media

Sara Ephraim Janine McCargo

+1-646-536-7002 +1-646-536-7033

sephraim@theruthgroup.com jmccargo@theruthgroup.com


'/>"/>
SOURCE Genetic Immunity
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
2. Response Genetics Reports Second Quarter 2007 Financial Results
3. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
6. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
7. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
8. Interleukin Genetics Announces Management and Board Appointments
9. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... Muncie, IN (PRWEB) , ... July 17, 2017 , ... ... 2017. The local celebration of National Model Aviation Day will take place from 9 ... is free and will include activities for all ages. , Aviation Adventure Day will ...
(Date:7/17/2017)... ... July 17, 2017 , ... Panitch Schwarze Belisario ... in the BiG (Biomedical Innovation Group) annual meeting in China. , This year’s ... antigen receptor T-cell) therapy, a rapidly developing highly personalized anti-cancer technology that involves ...
(Date:7/16/2017)... ... July 16, 2017 , ... ... analytical instruments announced the launch of its new line of Extreme Environment Shakers ... applications that require CO2 and humidity for optimal cell growth such as cell ...
(Date:7/14/2017)... , ... July 13, 2017 , ... ... and calibration verification test kit has received US FDA 510 (k) clearance for ... human plasma matrix, evaluates D-Dimer. Each VALIDATE® D-Dimer kit, prepared using the CLSI ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
Breaking Biology News(10 mins):